Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ...

The majority of CB1 receptors in the brain act on neurons, but some of these triggers are also found on non-neuronal cells called astrocytes. Astrocytes are the most common cell in the central nervous ...

CB1 inverse agonists have been shown to reduce appetite, and induce weight loss by several mechanisms, including increasing energy expenditure and a more rapid metabolism (Fig. 1) 1.

IGC Pharma has added HHS in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat agitation in ...

IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...

CB1 receptors are part of the endocannabinoid system and are primarily found in the brain. They play a role in mood regulation, memory and appetite, and are the primary targets of THC, the ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...